The American Society of Clinical Oncology (ASCO) has announced Jennifer A. Pietenpol, PhD, as the recipient of the 2024 ASCO Science of Oncology Award . This award acknowledges Dr. Pietenpol’s dedication and contributions to the field of global oncology.

Jennifer A. Pietenpol, is a professor of biochemistry at Vanderbilt University and a highly distinguished leader in scientific research known for her many contributions to the cancer field, including her transformative work on triple-negative breast cancer and the p53 family signaling network. Integrating expertise in tumor suppressor genes and molecular genetics with bioinformatic analyses of high-dimensional genomic data sets, she and her team subtyped difficult-to-treat triple-negative breast cancer. Her lab’s research has impacted many areas of science and medicine, and she has brought her lab’s discoveries to clinical impact for patients with breast cancer.

Dr. Pietenpol is chief scientific and strategy officer and executive vice president for research at Vanderbilt University Medical Center. She serves as a chief scientific advisor for the Susan G. Komen Foundation and is an active participant in various advisory boards, including those of NCI comprehensive cancer centers. Her contributions to oncology have been recognized through her appointment by President Bush to the National Cancer Advisory Board, where she served a 6-year term. She was a key member of the Blue Ribbon Panel, advising former Vice President Biden’s National Cancer Moonshot initiative.

About the Science of Oncology Award 

First awarded in 2005, this award is presented annually to an individual who has made outstanding contributions to basic or translational research in cancer.

The oncology community and our team at OncoDaily extend our congratulations to Dr. Jennifer A. Pietenpol on this deserving accolade, which highlights her significant impact on cancer research.